Adjuvant Herceptin regimens have become central to HER2-positive oncology protocols, driving robust demand for targeted monoclonal antibody therapies. Subcutaneous Herceptin formulations saw a 15% adoption increase in 2024 within hospital outpatient units, enhancing clinical efficiency. The Global Herceptin Market is estimated to be valued at USD 3.30 Bn in 2025 and is expected to rea... https://www.patreon.com/posts/herceptin-market-131379844